Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bonny Johnson

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 24, 2004
Transdermal delivery of desmopressin using a coated microneedle array patch systemMichel Cormier, Bonny Johnson, Mahmoud Ameri, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2004
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancerYun Yen, Kim Margolin, James Doroshow, et al.
Leukemia Research|July 21, 2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersJudith E Karp, Francis J Giles, Ivana Gojo, et al.
Leukemia Research|February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignanciesIvana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 24, 2004
Transdermal delivery of desmopressin using a coated microneedle array patch systemMichel Cormier, Bonny Johnson, Mahmoud Ameri, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2004
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancerYun Yen, Kim Margolin, James Doroshow, et al.
Leukemia Research|July 21, 2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersJudith E Karp, Francis J Giles, Ivana Gojo, et al.
Leukemia Research|February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignanciesIvana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Pageof 1